IMMUTEP CLASS ACTION LAWSUIT: A COMPREHENSIVE AND INFORMATIVE INVESTOR GUIDE [2026]
Key Details of the Immutep Class Action Lawsuit (May, 2026)
- Class Period in the Immutep class action lawsuit: All purchasers or acquirers of Immutep Limited (NASDAQ: IMMP) American Depositary Receipts (“ADRs”) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”).
- Lead Plaintiff Deadline: July 6, 2026.
- Core Allegations: The Immutep class action lawsuit alleges that executives falsely touted positive progress in the trial, despite internal knowledge of risks.
- Trigger Event: On March 13, 2026, Immutep announced the trial was being stopped due to recommendations from the Independent Data Monitoring Committee (IDMC) regarding futility.
- Market Impact: Immutep ADRs fell over 83%, from $2.76 to $0.48, following the announcement according to the Immutep class action lawsuit.
Introduction to the Immutep Class Action Lawsuit
- Who is Affected by the Immutep class action lawsuit? All purchasers or acquirers of Immutep Limited (NASDAQ: IMMP) American Depositary Receipts (“ADRs”) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”).
- The Problem: The Immutep class action lawsuit alleges the defendant made false and misleading statements driving the stock price artificially up until the truth emerged and the stock plummeted and shareholders who purchased during the relevant time period and suffered a loss are entitle to damages
- Your Action: You may be eligible to recover your losses in an Immutep class action lawsuit.
- Deadline to Lead: The deadline to apply to be Lead Plaintiff in the is Immutep class action lawsuit is July 6, 2026.
Key Aspects of the Immutep Class Action Lawsuit
The fraud: This involves a company or its executives intentionally making false or misleading statements to manipulate the stock market. This can include concealing important information that, if known, would have affected an investor’s decision to buy, sell, or hold the stock.
- The class period: This is the timeframe during which the alleged fraud took place. It typically starts when the misleading information is released and ends when the truth is fully disclosed to the public, often leading to a significant drop in the stock price. The class period in the Immutep class action lawsuit is March 24, 2025 and March 12, 2026.
- Investor eligibility: To be included, you must have purchased or sold the company’s securities during the class period and suffered an economic loss.
- Lead plaintiff: A court-approved lead plaintiff represents the entire class, oversees the Immutep class action lawsuit and has the authority to approve settlements on behalf of all class members.
- Legal basis: These lawsuits are based on federal and state securities laws, such as the Securities Act of 1933 and the Securities Exchange Act of 1934.
- Benefits: Class actions give individual investors leverage against large companies and allow them to share the costs of litigation through a contingency-fee arrangement, meaning the lawyers are paid only if the class wins.
- Participation: Investors who are eligible to join the class do not have to join and can “opt out” to pursue their own individual lawsuit, though this requires hiring and paying a private attorney.
How it Works
- A lawsuit is initiated by one or more investors, called the “lead plaintiffs,” on behalf of a larger group of investors, or the “class”.
- The “class period” is defined as the specific timeframe during which the alleged fraudulent activity took place. Only those who bought or sold the security during this period are eligible to participate.
- A lead plaintiff is appointed to represent the class. Under the Private Securities Litigation Reform Act (PSLRA), the court will typically appoint the investor with the largest financial interest in the outcome of the case.
- The case is litigated, which may include a lengthy discovery phase for gathering evidence.
- The case can be settled or go to trial. Most class actions are resolved through settlements, which can include cash or stock paid into a common fund for the class. The lead plaintiff and class counsel approve any settlement before it is finalized.
Common Types of Misconduct
- Securities fraud class actions can arise from various types of misconduct by a company, its officers, or others involved in the sale of its securities, including:
- Making false or misleading statements in SEC filings, prospectuses, or earnings announcements.
- Overstating a company’s revenues or profits through fraudulent or “creative” accounting.
- Failing to disclose material information that would significantly alter an investor’s view.
- Engaging in market manipulation to artificially inflate or deflate a security’s price.
What Plaintiffs Must Prove
To succeed in a federal securities fraud class action, plaintiffs must prove several elements:
- Material misstatement or omission: The company made a false or misleading statement, or failed to disclose a material fact.
- Scienter: The defendant acted with an intent to deceive, manipulate, or defraud.
- Reliance: The plaintiff relied on the misstatement or omission when buying or selling the security. For publicly traded securities, this can be proven through the “fraud-on-the-market” theory, which presumes the market price reflects all public, material information.
- Economic loss: The plaintiff suffered a financial loss.
- Loss causation: The company’s misstatement or omission directly caused the plaintiff’s loss, often demonstrated by a stock price drop after the truth is revealed in a “corrective disclosure“
Benefits for Investors
- Participating in a class action allows investors to pool their resources, which offers leverage they would not have in an individual lawsuit against a large corporation.
- The collective approach also makes it more efficient and cost-effective to pursue legal action, especially for smaller investors.
How to Get Involved
- If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.
- You may be notified of a class action by mail if you are an eligible class member.
- You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.
- If you believe you may have a claim, you can contact a securities class action law firm for guidance.
Lead Plaintiff Information
The Lead Plaintiff is the person or entity appointed by the court to represent the entire class in a securities class action or shareholder lawsuit.
This role involves a fiduciary duty to act in the best interests of all class members, making significant decisions throughout the litigation process.
To be appointed, a shareholder typically must show they have the largest financial interest in the relief sought and are capable of adequately protecting the class.
The deadline to move for appointment as Lead Plaintiff is strictly 60 days from the date the first class action notice is published.
Allegations in the Immutep Class Action Lawsuit
Immutep is a biotechnology company that engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. According to the complaint, Immutep’s TACTI-004 Phase III trial evaluated eftilagimod alfa (efti) in patients with advanced lung cancer.
The Immutep class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Defendants concealed and misrepresented the status and prospects of the TACTI-004 trial based on continuing positive efficacy and safety readouts of efti’s performance in other trials, particularly following positive top-line results from Immutep’s prior TACTI-002 and INSIGHT-003 studies;
- Defendants announced that the trial was exhibiting “strong operational progress” and the planned interim futility analysis remained “on track for the first quarter of CY2026”; and
- Immutep was aware of or was reckless, based on its access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints.
On March 13, 2026, defendants allegedly announced that the Independent Data Monitoring Committee (“IDMC”) for the TACTI-004 Phase III study evaluating efti in patients in first line non-small cell lung cancer recommended discontinuing the trial following a planned interim futility analysis. Defendants further allegedly announced that, “[b]ased on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility.”
On this news, the price of Immutep ADRs fell more than 82%, according to the Immutep class action lawsuit.
TIMOTHY L. MILES | FREE CASE EVALUATION
TAKE ACTION: CALL TODAY
"It will be the only call you need to make."
(855) TIM-M-LAW (855) 846-6529
Options Available to
Immutep
Shareholders
- Do Nothing (Remain a Class Member): This is the most common option. If you take no action, you automatically remain a member of the class.
- Exclude Yourself (Opt-Out): You have the absolute right to exclude yourself from the class action. This is often referred to as “opting out.”
- How to Exclude Yourself (Opt-Out): The process for opting out is not available immediately, but only when the class has been formally certified and a settlement or trial is imminent.
- Wait for the Class Notice: If a settlement is reached, the court will approve a Notice of Proposed Settlement that is mailed to all known class members.
- Review the Notice: This document will contain specific, formal instructions on how to exclude yourself from the settlement.
- Submit a Written Request: You must draft and mail a letter stating clearly that you wish to be excluded from the class action, and include all identifying information (name, address, shares sold, etc.).
- Meet the Deadline: Your exclusion request must be postmarked by the deadline in the Notice.
What Is a Shareholder Derivative Action?
A shareholder derivative action is a legal proceeding in which a shareholder brings a lawsuit on behalf of a company against its officers, directors, or other third parties for actions that have harmed the company.
This type of action allows shareholders to hold those responsible for misconduct accountable and seek remedies for any damages caused. Unlike traditional shareholder lawsuits, which are brought by individual shareholders seeking compensation for their own losses, a derivative action is brought on behalf of the company itself.
Rights of Investors
Investors affected by the Immutep class action lawsuit possess specific rights that they can exercise. Understanding these rights is vital for anyone considering involvement in the Immutep class action lawsuit.
Right to Information
- Investors have the right to receive accurate and timely updates regarding the Immutep class action lawsuit.
- This includes information on the case’s progress, potential settlements, and any necessary actions they may need to undertake.
Right to Participate
- Affected investors have the right to join the Immutep class action lawsuit.
- This allows them to collaborate with other investors in seeking compensation for their losses without the burden of filing individual lawsuits.
Right to Legal Representation
- Investors can seek legal counsel to navigate the complexities of the Immutep lawsuit.
- Legal professionals can provide guidance and support throughout the process.
- If you suffered substantial losses and wish to serve as lead plaintiff of the Immutep class action lawsuit or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].
What Damages Am I Entitled To?
- In a securities fraud case, the plaintiff’s damages are typically calculated as out-of-pocket losses.
- These losses are expressed as the difference between the price at which the stock was sold and the price at which the stock would have been sold absent any artificial inflation caused by the defendant’s alleged misrepresentations or omissions.
- Out-of-pocket losses refer to the actual financial losses experienced by investors as a result of the alleged misconduct of the defendant.
- These losses are typically calculated by comparing the purchase price of the securities with their value at the time of sale or other relevant measure of damages.
- The calculation may also take into account any dividends or other distributions received by the investor during the relevant period. It is important to note that in some cases, the calculation of out-of-pocket losses may be complicated by factors such as market fluctuations or other external events that may have affected the value of the securities.
- In such cases, expert analysis and economic modeling may be employed to determine an accurate estimation of the investor’s losses.
The Benefits of Serving as the Lead Plaintiff in the Immutep Class Action Lawsuit
Serving as a Lead Plaintiff has several advantages and important benefits.
- First, a Lead Plaintiff is able to negotiate more competitive attorney fees and reduce other litigation costs by actively monitoring the class counsel.
- Second, Lead Plaintiff has the benefit of being able to manage the litigation primarily by overseeing and monitoring the progress of the action and the efforts of counsel, and being able to review and comment on important filings and other documents pertaining to the prosecution of the action.
- Third, there is no financial risk in serving as a Lead Plaintiff because Lead Counsel advances all costs and expenses incurred in the prosecution of the case and will be reimbursed only if there is a successful settlement or judgment recovery on behalf of the class.
- Fourth, Lead Plaintiff has the benefit involved and active in all negotiations relating to any settlement.
- Finally, Lead Plaintiffs that continue owning the stock of the defendant will enjoy the long-term benefits from governance reform resulting from the litigation. Successful lawsuits with large punishments might have a stronger disciplining effect on a defendant’s management and raise awareness of the importance of corporate governance.
The Responsibilities of the Lead Plaintiff in the Immutep Lawsuit
- The Lead Plaintifff may select and retain counsel of their choosing to represent the class which importantly includes negotiating the contingent fees Lead Counsel will receive in the event of a settlement or judgment.
- Responsible for managing the litigation principally by overseeing and monitoring the progress of the action and the efforts of Lead Counsel.
- Lead Plaintiff will review, comment, and make suggestions on important court filings and other related documents pertaining to the prosecution of the class action.
- Lead Plaintiff will also participate in discovery, including gathering information that may involve answering interrogatories, producing documents and other evidence, and their sworn deposition taken before a court reporter.
- The Lead Plaintiff also attends hearings, trials, and other court proceedings.
- The Lead Plaintiff is to consult with the Lead Counsel about any possible settlements.
- Once settlement discussions began, the Lead Plaintiff will have an opportunity to be active in all negotiations.
- This may include attending mediations and being active in all aspects of the settlement.
- The Lead Plaintiff must approve any settlement before it is presented to a court.
Key Facts About Securities Class Action Lawsuits
- Common Causes: Lawsuits usually claim violations of the Securities Exchange Act of 1934 (Section 10(b) and Rule 10b-5) due to misleading information in SEC filings, press releases, or earnings calls.
- The “Class Period”: This is the time frame in which the stock was allegedly inflated. Investors must have bought shares during this period to be part of the class.
- Settlements and Trials: Less than 1% of cases go to trial, with most being dismissed or settled. In 2024, there were 88 settlements totaling roughly
- Median Recoveries: In 2024, the median settlement was roughly a million, a slight decrease from 2023 but still high compared to historical data.
- Lead Plaintiffs and Opt-Outs: Often, large institutional investors act as “lead plaintiffs.” Individual investors are generally notified and can participate or “opt out” to pursue their own, separate litigation.
- Statute of Limitations: Federal securities fraud cases generally have a limitation period of up to five years from the date of the alleged fraud.
Common Legal Claims
- Section 10(b) / Rule 10b-5: The most common claim, rrequiring proof of “scienter” (intent to defraud) and loss causation.
- Section 11: Used for misleading statements in registration documents; it has a lower burden of proof as it does not require showing intent to defraud.
- Common Allegations: Misrepresenting financial health, failing to disclose material weaknesses, or making false forward-looking performance
TIMOTHY L. MILES | FREE CASE EVALUATION
TAKE ACTION: CALL TODAY
"It will be the only call you need to make."
(855) TIM-M-LAW (855) 846-6529
Typical Litigation Process
- Filing & Lead Plaintiff: After an initial complaint, the court appoints a Lead Plaintiff, typically the investor with the largest financial interest.
- Motion to Dismiss: Defendants almost always file a motion to dismiss; in 2025, 62% of decided motions were granted by the courts.
- Class Certification: The court must officially certify the group as a “class” before the case can proceed on behalf of all affected investors.
- Discovery: A lengthy phase where parties exchange documents and testimony; this is often the most burdensome stage for defendant companies.
- Summary Judgement: Defendants argue that the facts after discovery do not state a claim for violation of the federal securities laws.
- Resolution: The vast majority of cases that are not dismissed end in a settlement rather than a trial. The median time to settlement is approximately 3.3 years.
- Court Approval and Notice: The court approves the settlement if it finds it is fair, adequate and reasonable and orders notice to be give to the class to participate in the settlement, object to the settlement or opt-out of the settlements.
- Administration. The Court appoints a third-party to administrate the settlement proceeds to class members.
When Is the Lead Plaintiff Deadline in the
Immutep Class Action Lawsuit
Under the Private Securities Litigation Reform Act (PSLRA), the plaintiff who files the first complaint has 20 days to publish the required notice of the pendency of the action.
- Notice Publication: Not later than 20 days after the complaint is filed, the plaintiff in the Immutep class action lawsuit must publish a notice advising other sharehoders of the pendency of the action.
- Lead Plaintiff Motion Deadline: Not later than 60 days after the date the notice is published.
- Court Consideration: The court must consider motions to consolidate and appoint a lead plaintiff no later than 90 days after the notice is published.
The Eligibility Criteria for Lead Plaintiff Appointment in the Immutep Class Action Lawsuit
To be eligible for appointment as the lead plaintiff in the Immutep Class Action Lawsuit, an investor must meet the following criteria:
- Securities Acquisition: The Immutep Class Action Lawsuit seeks to represent purchasers or acquirers of Immutep Limited (NASDAQ: IMMP) American Depositary Receipts (“ADRs”) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”).
- Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by Immutep and its executives.
- Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.
It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class Immutep Class Action Lawsuit as courts have consistently recognized the rights of non-U.S. investors in securities class actions.
Contingency Fee Agreements: No Cost to Hire a Lawyer
- No Fee: It does not cost anything to hire a lawyer if you are eligible for an Immutep lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
- Talk with a Lawyer Free of Charge: A lawyer can explain the process of an Immutep lawsuit and answer any questions you may have free of charge.
The Settlement Process in the Immutep Class Action Lawsuit
- Reaching a Tentative Agreement
- Negotiation: Attorneys for the lead plaintiff and defendants negotiate terms, often through mediation.
- MOU: Once they agree on a figure, they draft a Memorandum of Understanding (MOU) or a formal Stipulation of Settlement.
- Plan of Allocation: The parties develop a formula to determine how much each investor will receive based on their “recognized loss” during the class period.
- Preliminary Court Approval
- Initial Review: The judge reviews the settlement to ensure it is “fair, reasonable, and adequate” for the class members.
- Preliminary Order: If satisfied, the judge issues an order that schedules a final hearing and authorizes notice to the class.
- Class Notice and Claims Filing
- Notice: A court-appointed Claims Administrator sends notices to potential class members via mail or publication.
- Filing a Claim: To receive a payout, eligible investors must submit a Proof of Claim form with documentation of their stock trades (e.g., brokerage statements).
- Opt-Outs/Objections: Class members have a deadline to “opt out” (to sue individually) or “object” to the settlement terms in court.
- Final Approval and Distribution
- Final Fairness Hearing: The court holds a hearing to consider any objections and decide whether to grant final approval.
- Judgment: Once the judge signs the final judgment, the settlement becomes legally binding, and the lawsuit is dismissed.
- Payout: The Claims Administrator verifies all claims and distributes checks or direct deposits.
- Timeline: Payouts typically begin 9 to 12 months after final approval due to the complexity of auditing thousands of claims.
- Pro-Rata: Funds are usually distributed on a pro-rata basis, meaning your share depends on your specific losses relative to the total pool.
Advanced Red Flags and Warning Signs
One red flag to watch for is aggressive accounting practices, such as recognizing revenue prematurely or delaying expense recognition. These tactics can artificially inflate earnings and create a misleading picture of a company’s financial health. Investors should also scrutinize non-recurring or one-time items, as companies may use these as a means to smooth earnings and hide underlying issues.
- Corporate governance deficiencies often correlate with increased fraud risk. Warning signs include:
- Domineering management that discourages questions or dissent from board members
- Lack of independent directors or audit committee members with insufficient financial expertise
- Frequent changes in key personnel, particularly in financial reporting roles
- Poor communication between management and the board of directors
A pattern of frequent restatements or amendments to financial statements is also cause for concern, as it may indicate a lack of accuracy or transparency in financial reporting. When companies repeatedly revise their previously filed statements, it suggests either incompetence in financial reporting or deliberate manipulation that was later discovered.
Frequently Asked Questions About the Immutep Class Action Lawsuit
What initiated the Immutep class action lawsuit?
The Immutep class action lawsuit is initiated by investors alleging that Immutep provided misleading information regarding its financial health and operations, resulting in financial losses.
How can I join the Immutep class action lawsuit?
If you purchased shares during the class period and suffered a loss, then you are automatically a member of the Immutep lawsuit and do not need to do anything at this point unless you are considering moving for lead plaintiff.
What are the potential benefits of a Immutep class action lawsuit?
Class action lawsuits like the Immutep class action lawsuit allow individual investors to collectively seek justice and compensation, which might be challenging to pursue individually. They also promote corporate accountability.
How long will the Immutep class action lawsuit take to resolve?
The duration of class action lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the lawsuit.
What is the role of a lead plaintiff in the Immutep class action lawsuit?
A lead plaintiff is responsible for selecting and monitoring lead counsel responding to discovery requests, providing testimony when needed, reviewing key filings, and participating in settlement negotiations. They act as a fiduciary for the entire class, overseeing the litigation process to ensure the best possible outcome for all class members.
How does the court determine who becomes the lead plaintiff in the Immutep class action lawsuit?
The court typically appoints the investor with the largest financial interest in the case as the lead plaintiff, provided they meet the typicality and adequacy requirements of Rule 23. This is based on factors such as total class period purchases, net expenditures, and total losses. The appointed lead plaintiff must be capable of fairly representing the interests of the entire class.
Why We Rely on Decades of Legal Precedent
In 2026, we still rely on principles established 50 years ago because justice requires consistency. These "old" cases provide the battle-tested blueprints we use to hold modern corporations accountable today.
- Preventing "Moving Goalposts": Established law stops powerful defendants from changing the rules mid-case.
- Proven Results: Using decades of precedent ensures your rights are protected by the highest, most stable legal standards.
— Timothy L. Miles, Securities & Class Action Attorney
Contact Timothy L. Miles Today About a Immutep Class Action Lawsuit
The most important thing you need to know is you can call me at no charge if you wish to serve as lead plaintiff of the Immutep class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Facebook Linkedin Pinterest youtube
Visit Our Extensive Investor Hub: Learning for Informed Investors
